Peer-influenced content. Sources you trust. No registration required. This is HCN.
Medical Xpress
A repeat PSMA PET/CT scan detected recurrent disease in more than half of prostate cancer patients whose initial scan was negative. Findings altered management in nearly half of patients, particularly those with oligometastatic recurrence.
Hematology/Oncology July 28th 2026
Clinical Advances in Hematology & Oncology
A case-based application of FRESCO trial data positions fruquintinib as a third-line option in KRAS-mutant metastatic colorectal cancer, while emphasizing treatment decisions shift toward disease control and quality of life after multiple prior lines.
Hematology/Oncology July 13th 2026
Medical News Today (MNT)
A multivariable screening test detects 90% of clinically significant prostate cancers vs 74% with PSA alone, suggesting PSA thresholds may miss aggressive disease despite similar false-positive rates.
Oncology, Medical July 13th 2026
News Medical
A high-sensitivity KRAS-targeted blood test detects residual pancreatic cancer missed by standard assays, suggesting current monitoring approaches may underestimate recurrence risk despite treatment.
Gastroenterology July 13th 2026
Oncology News Central (ONC)
US cancer centers are enrolling fewer patients in clinical trials despite continued global therapeutic advances, raising concerns about access, competitiveness, and whether trials are fully integrated into standard oncology care.
Rare Disease Advisor
A retrospective cohort of 146 adult patients with T-cell ALL treated with a pediatric-inspired regimen at a single center achieved 3-year overall survival of 73% and leukemia-free survival of 77%, with age over 60 emerging as the primary adverse prognostic factor and early T-cell precursor phenotype showing no independent survival impact.
Hematology/Oncology June 22nd 2026